BeiGene, Ltd.

NasdaqGS:BGNE Stock Report

Market Cap: US$18.8b

BeiGene Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:BGNE Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Dec 24SellUS$7,700,043Baker Bros. Advisors LPCompany37,017US$208.01
09 Dec 24SellUS$186,500,000Baker Bros. Advisors LPCompany1,000,000US$186.50
02 Dec 24SellUS$3,568,500,000HHLR Advisors, Ltd.Company17,842,500US$200.00
01 Nov 24SellUS$10,445,631Capital Research and Management CompanyCompany50,971.7US$204.93
08 Oct 24SellUS$2,322,161John OylerIndividual10,000US$236.37
27 Sep 24SellUS$1,101,774Wang LaiIndividual5,000US$220.35
03 Sep 24SellUS$26,022Titus BallIndividual137US$189.94
30 Jul 24SellUS$133,915Chan LeeIndividual834US$160.57
09 Jul 24SellUS$2,422,077Capital Research and Management CompanyCompany218,414.99US$11.09
01 Jul 24SellUS$67,919Julia WangIndividual472US$143.90
24 Jun 24SellUS$445,070John OylerIndividual2,789US$160.12
24 Jun 24SellUS$233,133Xiaobin WuIndividual1,459US$161.27
24 Jun 24SellUS$139,938Julia WangIndividual899US$155.66
24 Jun 24SellUS$170,030Wang LaiIndividual1,064US$161.10
18 Jun 24SellUS$368,162Wang LaiIndividual2,341US$159.90
18 Jun 24SellUS$505,208Xiaobin WuIndividual3,254US$159.00
17 Jun 24SellUS$69,955Chan LeeIndividual439US$159.74
17 Jun 24SellUS$204,125John OylerIndividual1,281US$159.91
17 Jun 24SellUS$145,678Julia WangIndividual916US$159.74
11 Apr 24SellUS$7,475,024John OylerIndividual50,000US$154.21
29 Feb 24SellUS$66,331Julia WangIndividual397US$167.08
26 Jan 24BuyUS$23,699,905Capital Research and Management CompanyCompany146,849.93US$161.39

Insider Trading Volume

Insider Buying: BGNE insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of BGNE?
Owner TypeNumber of SharesOwnership Percentage
Employee Share Scheme138,2400.13%
Private Companies368,3850.347%
Individual Insiders4,786,7334.51%
General Public15,971,83315%
Hedge Funds18,119,22417.1%
Public Companies18,938,11917.8%
Institutions47,923,66045.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2%.

Top Shareholders

Top 25 shareholders own 73.06% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
17.8%
Amgen Inc.
18,938,119US$3.3b0%no data
8.98%
Baker Bros. Advisors LP
9,536,552US$1.7b-9.83%16.91%
8.08%
HHLR Advisors, Ltd.
8,582,672US$1.5b-16.5%20.19%
6.98%
Capital Research and Management Company
7,412,076US$1.3b-0.92%0.06%
4.68%
PRIMECAP Management Company
4,974,289US$878.0m-0.24%0.63%
3.67%
Baillie Gifford & Co.
3,895,929US$687.6m0.66%0.29%
3.48%
John Oyler
3,697,262US$652.6m-11.1%no data
2.79%
BlackRock, Inc.
2,962,457US$522.9m5.02%0.01%
2.54%
T. Rowe Price Group, Inc.
2,700,341US$476.6m18.8%0.04%
2.3%
The Vanguard Group, Inc.
2,438,763US$430.4m0.77%0.01%
2.25%
Temasek Holdings (Private) Limited
2,388,576US$421.6m-20.8%0.36%
1.54%
FMR LLC
1,640,542US$289.6m0.9%0.02%
1.08%
Bosera Asset Management Co., Ltd.
1,150,829US$203.1m0%0.95%
1.03%
Norges Bank Investment Management
1,090,871US$192.5m0%0.02%
0.97%
Hillhouse Investment Management, Ltd.
1,034,485US$182.6m-80%1.65%
0.73%
Xiaodong Wang
776,677US$137.1m-11.4%no data
0.68%
GF Fund Management Co., Ltd.
717,207US$126.6m0%0.27%
0.64%
Point72 Asset Management, L.P.
680,715US$120.1m78.5%0.3%
0.53%
Artal Group S.A.
563,314US$99.4m85.7%2.97%
0.47%
Tavistock Life Sciences
500,000US$88.3m0%6.15%
0.42%
China Asset Management Co. Ltd.
448,116US$79.1m-3.51%0.1%
0.37%
ICBC Credit Suisse Asset Management Co., Ltd.
398,099US$70.3m0%0.49%
0.35%
Guangzhou Development District Holding Group Limited
368,385US$65.0m0%no data
0.35%
SDIC Unity Capital Co., Ltd.
368,385US$65.0m0%7.01%
0.33%
Public Investment Fund
354,385US$62.5m0%0.03%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 01:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BeiGene, Ltd. is covered by 57 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Michael MengBOCI Research Ltd.
Yonglin YanBOCI Research Ltd.